SCHEMBL1222473

SCHEMBL1222473

Cc1ccnc(Cl)c1I

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31717812 1.00
SCHEMBL14844472 0.84 NOS2 (0.34)
SCHEMBL2263414 0.77 LMNA (0.46)
SCHEMBL17080405 0.76
SCHEMBL3725494 0.75
SCHEMBL12896120 0.75
SCHEMBL5644419 0.75
SCHEMBL738704 0.75
SCHEMBL170573 0.75
SCHEMBL28391211 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117024411-B Isoquinoline as HPK1 inhibitor 豪夫迈·罗氏有限公司 2026-05-19 CN disclosed
US-20260125364-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2026-05-07 US disclosed
US-12600728-B2 Interleukin-17 inhibitors NOVARTIS AG (CH) 2026-04-14 US disclosed
US-20260062425-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2026-03-05 US disclosed
US-12338256-B2 Aza-tetracyclic oxazepine compounds and uses thereof GENENTECH, INC. (US) 2025-06-24 US disclosed
EP-4526309-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF Genentech, Inc. (US) 2025-03-26 EP disclosed
CN-119365467-A Aza-tetraepoxy aza compounds and uses thereof 基因泰克公司 2025-01-24 CN disclosed
US-20240368186-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2024-11-07 US disclosed
US-20240317713-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2024-09-26 US disclosed
US-11964961-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2024-04-23 US disclosed
WO-2009132774-A1 NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P39 MITOGEN-ACTIVATED KINASE INHIBITORS ALMIRALL, S. A. (ES) 2009-11-05 WO disclosed
EP-2113503-A1 New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors Laboratorios Almirall, S.A. (ES) 2009-11-04 EP disclosed
EP-2113503-A1 New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors Laboratorios Almirall, S.A. (ES) 2009-11-04 EP disclosed
US-20090156596-A1 Unsaturated Heterocyclic Derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
EP-1940843-A2 UNSATURATED HETEROCYCLIC DERIVATIVES ARIAD PHARMACEUTICALS, INC. (US) 2008-07-09 EP disclosed
WO-2007021937-A2 UNSATURATED HETEROCYCLIC DERIVATIVES ARIAD PHARMACEUTICALS, INC. (US) 2007-02-22 WO disclosed
EP-0999859-A2 USE OF HYALURONIC ACID DERIVATIVES IN THE PREPARATION OF BIOMATERIALS FIDIA ADVANCED BIOPOLYMERS S.R.L. (IT) 2000-05-17 EP disclosed
EP-0971961-A1 N-SULPHATED HYALURONIC ACID COMPOUNDS, DERIVATIVES THEREOF AND A PROCESS FOR THEIR PREPARATION FIDIA ADVANCED BIOPOLYMERS S.R.L. (IT) 2000-01-19 EP disclosed
WO-1999004828-A2 USE OF HYALURONIC ACID DERIVATIVES IN THE PREPARATION OF BIOMATERIALS FIDIA ADVANCED BIOPOLYMERS, S.R.L. (IT) 1999-02-04 WO disclosed
WO-1998045335-A1 N-SULPHATED HYALURONIC ACID COMPOUNDS, DERIVATIVES THEREOF AND A PROCESS FOR THEIR PREPARATION FIDIA ADVANCED BIOPOLYMERS, S.R.L. (IT) 1998-10-15 WO disclosed